Evidence supporting the use of: Astragaloside IV
For the health condition: Nephritis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Astragaloside IV, a major active component extracted from the traditional Chinese medicinal herb Astragalus membranaceus, has been investigated in preclinical studies for its potential protective effects in nephritis and other kidney diseases. The majority of evidence comes from animal models and in vitro studies, where Astragaloside IV has demonstrated anti-inflammatory, antioxidative, and anti-fibrotic properties. For example, research published in peer-reviewed journals (such as Phytomedicine and International Immunopharmacology) reports that Astragaloside IV can reduce proteinuria, inhibit renal cell apoptosis, and suppress the expression of pro-inflammatory cytokines in rodent models of nephritis.

The proposed mechanisms include regulation of the NF-κB pathway, attenuation of oxidative stress, and improvement of podocyte function. However, clinical evidence in humans is very limited, with only a few small pilot studies or case reports available, and there are no large randomized controlled trials establishing its efficacy or safety for nephritis in humans. Thus, the use of Astragaloside IV for nephritis is primarily supported by preclinical experimental data rather than robust clinical trial evidence. It is not a standard or approved therapy in Western medicine, though it may be used in some integrative or traditional medical settings in China as an adjunct.

In summary, there is some scientific validation at the preclinical level, but the overall evidence base is weak (rated 2/5), and further human studies are needed to confirm its therapeutic potential.

More about Astragaloside IV
More about Nephritis

Products containing Astragaloside IV

We currently have no products on Vitabase that contain this ingredient.